In the attempt to decipher HCC molecular signature and to optimize personalized treatments, Kim et al. performed an exome sequencing analysis of NAFLD-HCC tumor samples and revealed that Telomerase reverse transcriptase (TERT) promoter mutations occurred in 82% of cases, followed by Catenin beta 1 (CTNNB1) (45%) and TP53 (36%) mutations [65]. This evidence concerns the gene CTNNB1 and metabolic dysfunction-associated steatotic liver disease.